All In Biotech

NDA 218037 · Alexion Pharms INC

Voydeya

Danicopan · Oral · Complement Factor D Inhibitor

NovelBreakthrough therapyOrphan

CDER novel approval, Mar 29, 2024: To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria

Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Mar 29, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

26

3 Phase 3, 1 recruiting

FAERS reports

310

242 serious, 20 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA VOYDEYA, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Neisseria meningitidis , Streptococcus pneumoniae , and Haemophilus influenzae type B [ see Warnings and Precautions (5.1) ]. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update vaccination for encapsulated bacteria specifically, Neisseria meningitidis and Streptococcus pneumoniae at least 2 weeks prior to the first dose of VOYDEYA, unless the risks of delaying therapy with VOYDEYA outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices...

What it is approved for

From the label in effect May 12, 2026.

VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). VOYDEYA is a complement factor D inhibitor indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH) ( 1 ). Limitations of Use VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab. Limitations of Use VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab.

Mechanism: Danicopan binds reversibly to complement Factor D and selectively inhibits the alternative complement pathway. Danicopan prevents the cleavage of complement Factor B into the Ba and Bb fragments which are required for the formation of the alternative pathway (AP) complement component C3 convertase (C3bBb), the generation of downstream effectors including C3 fragment opsonization, and the amplification of the terminal pathway. In PNH, intravascular hemolysis (IVH) is mediated by the terminal membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3 fragment...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 29, 2024 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyOrphanLetterReview
2 products under this application
  • VOYDEYA · DANICOPAN 100MG · TABLET, ORAL · Prescription
  • VOYDEYA · DANICOPAN 50MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Danicopan" as an intervention, any sponsor and status, largest first.

All 26 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • haemoglobin decreased36
  • haemolysis28
  • fatigue24
  • breakthrough haemolysis23
  • extravascular haemolysis20
  • drug ineffective17
  • off label use17
  • pneumonia17
  • anaemia16
  • headache14
  • diarrhoea13
  • covid-1912

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20232
202475
2025122
2026111

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Voydeya (Danicopan)

2024 spending

$499K

Beneficiaries

32

120 claims

Per beneficiary

$15,603

$23.37 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$499,298

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.